Vulvar Part 2: Advanced
This is the second of three episodes covering vulvar cancer. In this episode we review the evolution and management of locally advanced vulvar cancer, discuss the utility of chemoradiation versus radiation alone, review the data on systemic therapy and biomarker directed therapies, and explore treatment options for progressive and recurrent vulvar cancer.
Vulvar Part 1: Early Stage
This is the first of three episodes covering vulvovaginal cancer. In this episode we discuss the epidemiology and prognostic markers for vulvar cancer, review the staging of vulvar cancer, and explore the treatment for early stage vulvar cancer.
Radiation: Toxicities
In our second episode on radiation oncology, we review acute and chronic toxicities of therapeutic radiation, with a focus on organ-specific toxicities. We also discuss diagnosis and management of radiation emergencies.
Radiation: The fundamentals
In this episode, we discuss the fundamentals of radiation oncology for the gynecologic oncologist. We’ll review radiation physics and biology, radiation sources, types of administration of radiation in gynecologic cancers, and general principles of dosing and fractionation.
Cervix: Part 3
The third and final part of our series on the Cervix. This episode covers the current standard of care in cervical cancer, including new options for treatment of persistent, metastatic, and recurrent cervical cancer.
Cervix Part 2
This is the second of three episodes covering cervical cancer. In this episode, we define locally advanced, metastatic, and recurrent cervical cancer. We will discuss the standard treatment options, including chemotherapy and immunotherapy choices.
Cervix Part 1
This is the first of three episodes covering cervical cancer. In this episode, we discuss the epidemiology, risk factors, and staging of cervical cancer. In addition, we review the role of surgical management in early stage cervical cancer.
Chemotherapy: HIPEC and IPC
In this episode, we discuss Intraperitoneal chemotherapy (IPC) and Heated Intraperitoneal Chemotherapy (HIPEC), including clinical trials of these agents in ovarian cancer and practical tips for utilizing HIPEC in clinical practice.
Chemotherapy: PARP-I, Bevacizumab, and Ovarian Cytotoxics
Chemotherapy: PARP-I, Bev, Ovarian Cytotoxics
In this episode, we discuss antineoplastic agents for ovarian cancer. We discuss PARP-inhibitors, homologous recombination deficiency, bevacizumab, as well as new cytotoxic chemotherapy used in the treatment of ovarian cancers.
Ovary Part 7
In part 7 of our ovarian cancer series, we discuss surgical considerations in ovarian cancer, including patient and disease-specific factors that can influence surgical decision making, methods to predict optimal cytoreduction, and the utility of secondary cytoreduction.